新华时评·民生无小事｜惩治“阴阳价”！定点药店岂能“看人下菜碟”

Core Points - The article highlights the issue of "yin-yang pricing" in designated pharmacies, where the same cold medicine is priced at 17 yuan for non-insured individuals and 31 yuan for insured individuals, indicating a significant price discrepancy that undermines public trust in the healthcare system [1][2] - The government has issued a notification to strengthen monitoring and handling of "yin-yang pricing" practices in pharmacies, emphasizing the need for strict investigations and penalties against violators [1] - Collaboration among healthcare, market regulation, and drug supervision departments is essential to effectively combat "yin-yang pricing" and protect the integrity of the medical insurance fund [1] Summary by Sections Issue Identification - Designated pharmacies are engaging in "yin-yang pricing," which harms the interests of insured individuals and erodes trust in the medical insurance system [1] - The lack of transparency in drug pricing and the insensitivity of insured individuals to drug prices contribute to the prevalence of this issue [1] Government Response - A recent notification has been issued to address "yin-yang pricing," mandating serious investigations and potential penalties for pharmacies involved in such practices [1] - Measures may include interviews, suspension of medical insurance settlements, and termination of medical service agreements based on the severity of the violations [1] Preventive Measures - The article suggests leveraging technology to combat "yin-yang pricing" by promoting drug price comparison apps and implementing drug traceability codes to create a comprehensive supervision network [2] - Public reporting channels should be prominently displayed in pharmacies to enhance community oversight [2] - The article emphasizes that the qualification for designated pharmacies should be viewed as a responsibility for honest business practices rather than a license for unregulated operations [2]